<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JHEP Rep</journal-id><journal-id journal-id-type="iso-abbrev">JHEP Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3793</journal-id><journal-id journal-id-type="pmc-domain">jhepr</journal-id><journal-title-group><journal-title>JHEP Reports</journal-title></journal-title-group><issn pub-type="epub">2589-5559</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10017423</article-id><article-id pub-id-type="pmcid-ver">PMC10017423.1</article-id><article-id pub-id-type="pmcaid">10017423</article-id><article-id pub-id-type="pmcaiid">10017423</article-id><article-id pub-id-type="pmid">36937989</article-id><article-id pub-id-type="doi">10.1016/j.jhepr.2023.100696</article-id><article-id pub-id-type="pii">S2589-5559(23)00027-7</article-id><article-id pub-id-type="publisher-id">100696</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Environmental exposures are important risk factors for advanced liver fibrosis in African American adults</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Ma</surname><given-names initials="N">Ning</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Yip</surname><given-names initials="R">Rowena</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Lewis</surname><given-names initials="S">Sara</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Dinani</surname><given-names initials="A">Amreen</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Wyatt</surname><given-names initials="C">Christina</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Crane</surname><given-names initials="M">Michael</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Jirapatnakul</surname><given-names initials="A">Artit</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Li</surname><given-names initials="L">Li</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Aloman</surname><given-names initials="C">Costica</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Bansal</surname><given-names initials="MB">Meena B.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Dieterich</surname><given-names initials="D">Douglas</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Wyatt</surname><given-names initials="B">Brooke</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Yankelevitz</surname><given-names initials="D">David</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Henschke</surname><given-names initials="C">Claudia</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Branch</surname><given-names initials="AD">Andrea D.</given-names></name><email>andrea.branch@mssm.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>1</label>Division of Liver Diseases, Icahn School of Medicine Mount Sinai, New York, NY, USA</aff><aff id="aff2"><label>2</label>Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="aff3"><label>3</label>Department of Medicine, Division of Nephrology, Duke University School of Medicine, Durham, NC, USA</aff><aff id="aff4"><label>4</label>Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="aff5"><label>5</label>Department of Medicine, Rush University Medical Center, Chicago, IL, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. Address: Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1123, New York, NY 10029, USA. Tel.: +1-212-659-8371; Fax: +1-212-849-2574. <email>andrea.branch@mssm.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>06</day><month>2</month><year>2023</year></pub-date><volume>5</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">429952</issue-id><elocation-id>100696</elocation-id><history><date date-type="received"><day>20</day><month>10</month><year>2022</year></date><date date-type="rev-recd"><day>10</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>02</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>17</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-03-20 10:10:24.700"><day>20</day><month>03</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Author(s)</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background &amp; Aims</title><p>The prevalence and aetiology of liver fibrosis vary over time and impact racial/ethnic groups unevenly. This study measured time trends and identified factors associated with advanced liver fibrosis in the United States.</p></sec><sec><title>Methods</title><p>Standardised methods were used to analyse data on 47,422 participants (&#8805;20 years old) in the National Health and Nutrition Examination Survey (1999&#8211;2018). Advanced liver fibrosis was defined as Fibrosis-4 &#8805;2.67 and/or Forns index &#8805;6.9 and elevated alanine aminotransferase.</p></sec><sec><title>Results</title><p>The estimated number of people with advanced liver fibrosis increased from 1.3 million (95% CI 0.8&#8211;1.9) to 3.5 million (95% CI 2.8&#8211;4.2), a nearly threefold increase. Prevalence was higher in non-Hispanic Black and Mexican American persons than in non-Hispanic White persons. In multivariable logistic regression analysis, cadmium was an independent risk factor in all racial/ethnic groups. Smoking and current excessive alcohol use were risk factors in most. Importantly, compared with non-Hispanic White persons, non-Hispanic Black persons had a distinctive set of risk factors that included poverty (odds ratio [OR] 2.09; 95% CI 1.44&#8211;3.03) and susceptibility to lead exposure (OR 3.25; 95% CI 1.95&#8211;5.43) but did not include diabetes (OR 0.88; 95% CI 0.61&#8211;1.27; <italic toggle="yes">p</italic>&#160;=0.52). Non-Hispanic Black persons were more likely to have high exposure to lead, cadmium, polychlorinated biphenyls, and poverty than non-Hispanic White persons.</p></sec><sec><title>Conclusions</title><p>The number of people with advanced liver fibrosis has increased, creating a need to expand the liver care workforce. The risk factors for advanced fibrosis vary by race/ethnicity. These differences provide useful information for designing screening programmes. Poverty and toxic exposures were associated with the high prevalence of advanced liver fibrosis in non-Hispanic Black persons and need to be addressed.</p></sec><sec><title>Impact and Implications</title><p>Because liver disease often produces few warning signs, simple and inexpensive screening tests that can be performed by non-specialists are needed to allow timely diagnosis and linkage to care. This study shows that non-Hispanic Black persons have a distinctive set of risk factors that need to be taken into account when designing liver disease screening programs. Exposure to exogenous toxins may be especially important risk factors for advanced liver fibrosis in non-Hispanic Black persons.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0010">The prevalence of advanced liver fibrosis doubled in the past 20 years in the United States.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0015">Prevalence was higher in non-Hispanic Black persons than in non-Hispanic White persons.</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0020">Risk factors in non-Hispanic Black persons included lead exposure, but not diabetes.</p></list-item><list-item id="u0025"><label>&#8226;</label><p id="p0025">Cadmium was a risk factor in all racial/ethnic groups examined.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Environmental toxins</kwd><kwd>Racial disparities</kwd><kwd>Aetiology</kwd><kwd>Non-invasive scores</kwd><kwd>Screening</kwd></kwd-group><kwd-group id="kwrds0015"><title>Abbreviations</title><kwd>ALD, alcohol-associated liver disease</kwd><kwd>ALT, alanine aminotransferase</kwd><kwd>APC, annual percent change</kwd><kwd>BMI, body mass index</kwd><kwd>CI, confidence interval</kwd><kwd>FIB-4, Fibrosis-4</kwd><kwd>HBV, hepatitis B virus</kwd><kwd>HCV, hepatitis C virus</kwd><kwd>HR, hazard ratio</kwd><kwd>KI, kidney insufficiency</kwd><kwd>LF, liver fibrosis</kwd><kwd>MA, Mexican American</kwd><kwd>NAFLD, non-alcoholic fatty liver disease</kwd><kwd>NEI, no exposure identified</kwd><kwd>NHANES, National Health and Nutrition Evaluation Survey</kwd><kwd>NHB, non-Hispanic Black</kwd><kwd>NHW, non-Hispanic White</kwd><kwd>O, other race</kwd><kwd>PCB, polychlorinated biphenyl</kwd><kwd>Q1&#8211;Q4, quartiles 1&#8211;4</kwd><kwd>ULN, upper limit of normal</kwd><kwd>USFLI, US Fatty Liver Index</kwd><kwd>VH, viral hepatitis</kwd><kwd>WC, waist circumference</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0030">Liver disease causes an estimated 2 million deaths globally each year<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> but is under-diagnosed. In a recent US study, nearly 50% of primary care patients who experienced a serious liver-related event did not have a prior diagnosis of liver disease.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Similarly, in the United Kingdom, &#8216;around three-quarters of patients who will die from cirrhosis are currently unaware that they have liver disease&#8217;.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Increased diagnosis will require screening for liver fibrosis (LF) in primary care settings.</p><p id="p0035">The Fibrosis-4 (FIB-4) index provides a validated estimate of LF risk.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> An American Gastroenterology Association task force reported that &#8216;it provides a useful, inexpensive, first-line assessment of liver fibrosis for use in primary care&#8217;.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> The Forns index is a second well-validated non-invasive fibrosis test.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> In the National Health and Nutrition Examination Survey (NHANES) population, FIB-4 &#8805;2.67 and Forns &#8805;6.9 have hazard ratios (HRs) for liver-related death of 42 and 117, respectively.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> When combined with alanine aminotransferase (ALT) elevation, both FIB-4 and Forns indices had areas under the receiver operating curve of 0.83 for predicting serious liver-related events over 10 years in the community setting.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Several additional screening tests have been proposed, and it is likely that one or more will be broadly implemented soon.<xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref></p><p id="p0040">The American Association for the Study of Liver Diseases is currently developing guidelines for non-invasive LF screening.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> According to EASL guidelines,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> screening should be limited to individuals with known risk factors, such as type 2 diabetes. This restriction raises questions about which risk factors can be relied on to yield equitable and inclusive screening protocols.</p><p id="p0045">Comprehensive information about risk factors in the multi-ethnic population of the United States is lacking, but essential, particularly if screening is going to be limited to patients with specific risk factors. Given the high accuracy of FIB-4 and Forns indices when combined with elevated ALT to identify individuals at high risk for liver-related events,<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> the objectives of this study are to use the nationally representative NHANES data (1) to determine time trends, (2) to compare risk factors among racial/ethnic groups, and (3) to determine the percentage of people with advanced LF who might be missed by aetiology-based screening. The results show that the prevalence of advanced fibrosis nearly doubled over the past 20 years and was higher in non-Hispanic Black (NHB) persons than in non-Hispanic White (NHW) persons. NHB persons had a distinctive set of risk factors that included lead and poverty but did not include diabetes or hypertension, which were risk factors in NHW persons. These differences need to be considered in risk factor-based screening guidelines. High cadmium exposure was a risk factor in all racial/ethnic groups, highlighting the potential role of environmental toxins in LF.</p></sec><sec id="sec2"><title>Materials and methods</title><sec id="sec2.1"><title>Study population and data sources</title><p id="p0050">NHANES uses standardised procedures to collect data under a protocol approved by the National Center for Health Statistics Research Ethnic Review Board. Analysis of de-identified NHANES data is exempt from institutional review board review.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Ten cycles of NHANES (1999&#8211;2018) were used in the main analyses (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwn.cdc.gov/nchs/nhanes/Default.aspx" id="intref0010">https://wwwn.cdc.gov/nchs/nhanes/Default.aspx</ext-link>). Sub-studies used liver ultrasound data from NHANES III (1988&#8211;1994) and measurements of organic chemicals (polychlorinated biphenyls [PCBs]) from NHANES 2003&#8211;2004. The public-use linked mortality file was obtained through 2019.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref></p></sec><sec id="sec2.2"><title>Indicators of fibrosis</title><p id="p0055">FIB-4 and Forns indices were calculated as before.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Advanced LF was indicated by FIB-4 &#8805;2.67 and/or Forns &#8805;6.9 and ALT above the upper limit of normal (ULN) (&#8805;40 IU/L for men and &#8805;31 IU/L for women).</p></sec><sec id="sec2.3"><title>Demographic variables</title><p id="p0060">Analysis used self-reported sex (male/female) and race/ethnicity (NHW, NHB, Mexican American [MA], and other race [O; non-MA Hispanic and others]). The main analysis was performed on people aged 20&#8211;85 years. Sensitivity analyses were conducted on people aged 35&#8211;64 years because FIB-4 may underestimate fibrosis in individuals younger than 35 years<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> and because changes in health insurance may alter association with poverty after age 64 years.</p></sec><sec id="sec2.4"><title>Definition of risk factors</title><p id="p0065">Kidney insufficiency (KI) was a urinary albumin-to-creatinine ratio &#8805;30&#160;mg/g and/or an estimated glomerular filtration rate &lt;60&#160;ml/min/1.73&#160;m<sup>2</sup>, calculated using the Chronic Kidney Disease Epidemiology Collaboration 2021 creatinine-based formula (race agnostic).<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Diabetes was self-reported, and/or haemoglobin A<sub>1c</sub> &#8805;6.5%, and/or fasting plasma glucose &#8805;126&#160;mg/dl.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Hypertension was systolic blood pressure &#8805;130&#160;mmHg, and/or diastolic blood pressure &#8805; 80&#160;mmHg, and/or use of antihypertensive medication.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> BMI was categorised as normal weight (&lt;25&#160;kg/m<sup>2</sup>), overweight (25 &#8804;BMI &lt;30&#160;kg/m<sup>2</sup>), and obese (&#8805;30&#160;kg/m<sup>2</sup>). Waist circumference (WC) was categorised as normal (&lt;94&#160;cm for men and &lt;80&#160;cm for women), moderate (94 &#8804;WC &lt;102&#160;cm for men and 80 &#8804;WC &lt;88&#160;cm for women), and high (&#8805;102&#160;cm for men and &#8805;88&#160;cm for women).<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> Metabolic syndrome was defined as &#8805;3 of the following: WC &#8805;102&#160;cm for men and &#8805;88&#160;cm for women; triglyceride &#8805;150&#160;mg/dl; HDL cholesterol &lt;40&#160;mg/dl for men and &lt;50&#160;mg/dl for women; systolic blood pressure &#8805;130&#160;mmHg or diastolic blood pressure &#8805;85&#160;mmHg or taking hypertension medications; and fasting plasma glucose &#8805;100&#160;mg/dl.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Past/current smokers answered &#8216;Yes&#8217; to the question &#8216;Have you smoked at least 100 cigarettes in your lifetime?&#8217; Never smokers answered &#8216;No&#8217;.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> The responses to questions about alcohol consumption were used to create four mutually exclusive groups, lifetime abstainers (&lt;12 drinks in lifetime), former drinkers (&#8805;12 drinks in their lifetime but none in the past year), non-excessive current drinkers (on average, &#8804;14 drinks/week for men and &#8804;7 drinks/week for women, and never &#8805;5 in a single day during the past year for either), and excessive current drinkers (on average, &gt;14 drinks/week for men and &gt;7 drinks/week for women, or &gt;5 drinks in a single day at least once during the past year for either).<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Blood levels of lead and cadmium were analysed as continuous and binary variables (quartile 1 [Q1]&#8211;Q3 <italic toggle="yes">vs</italic>. Q4). Lipid-adjusted plasma levels of PCBs were classified by quartiles (Q1&#8211;Q3 <italic toggle="yes">vs</italic>. Q4) (see <xref rid="appsec1" ref-type="sec">Fig.&#160;S6</xref> for details).<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Poverty was defined as a family poverty&#8211;income ratio below 1.0.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref></p></sec><sec id="sec2.5"><title>Definitions of disease aetiologies</title><p id="p0070">Disease aetiology was examined in participants who had data for calculating the US Fatty Liver Index (USFLI), which was previously validated for the US population.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Viral hepatitis (VH) was past/current infection with HBV, positive HBV core antibody, or HBsAg; or HCV, RNA, or antibody. Alcohol-associated liver disease (ALD) was meeting previous criteria: consuming on average &gt;14 drinks/week (women) or 21 drinks/week (men) in the past 12 months, and having elevated liver enzymes, AST, or ALT (&gt;25 U/L in women and 35 U/L in men)<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> and/or categorised as current excessive drinker<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> in this study. Non-alcoholic fatty liver disease (NAFLD) was USFLI &#8805;30.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> No exposure identified (NEI) was not meeting criteria for VH, ALD, or NAFLD. In sensitivity analyses, NAFLD was defined by abdominal ultrasound (mild/moderate/severe fatty liver) from NHANES III.</p></sec><sec id="sec2.6"><title>Statistical analysis</title><p id="p0075">All analyses were conducted according to NHANES guidelines,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> using established methods to combine cycles. Data were adjusted for the complex NHANES design with strata, primary sampling units, and probability weights incorporated into statistical models using the survey estimation commands in SAS OnDemand for Academics (SAS Institute Inc., Cary, NC, USA). These procedures generate estimates for the housed, civilian, noninstitutionalised population in the United States. Age standardisation estimates were calculated using the direct method, standardised to the 2000 US census population with four age categories for the 20- to 85-year age group and three age categories for the 35- to 64-year age group. Differences between groups were tested by univariate <italic toggle="yes">t</italic> statistics.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> To estimate the number of adults with advanced LF, prevalence was calculated and then multiplied by the estimated adult US population obtained from the Current Population Surveys or American Community Survey of each survey cycle.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Annual percent changes (APCs) were calculated using the Joinpoint Regression Program (Version 4.9.0.0, National Cancer Institute).<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> Univariable and multivariable survey logistic regression with appropriate sample weights were used to examine the association between advanced LF and the independent variables. Survey-weighted adjusted multivariable Cox proportional models were used to investigate the association between advanced-LF and all-cause mortality. The minimal 10 events per variable rule was used to determine the minimal sample size required in models.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Missing values that ranged from 0.1% to 9.0% were addressed using multivariable imputation by chained equations.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Combined estimates using 10 imputed datasets were calculated. Statistical significance was a two-sided <italic toggle="yes">p</italic> value &lt;0.05.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Threefold increase in cases of advanced LF over 20 years</title><p id="p0080">The selection of the study group is presented in <xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>, and the dynamic time trends of advanced LF are presented in <xref rid="fig2" ref-type="fig">Fig.&#160;2</xref>. The estimated number of people with advanced LF increased from 1.3 million (95% CI 0.8&#8211;1.9) to 3.5 million (95% CI 2.8&#8211;4.2), a nearly threefold increase over 20 years (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref>A). The age-standardised weighted prevalence approximately doubled (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref>B). The APC was 8.7% (95% CI 6.7&#8211;10.9) (<xref rid="appsec1" ref-type="sec">Table&#160;S1</xref>). The prevalence of advanced LF was about 1.6-fold higher in NHB persons than in NHW persons in the total group and in men and women when analysed separately (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref>C and D). The HR for all-cause mortality among people with advanced LF was 2.42 (95% CI 1.96&#8211;2.97) in the 20- to 85-year age group and 3.86 (95% CI 2.78&#8211;5.37) in the 35- to 64-year age group (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>B and C).<fig id="fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Flowchart of participant selection and association between advanced fibrosis and all-cause mortality.</p><p>(A) Flowchart of participant selection (47,442 adults were included in the analysis); all-cause mortality in (B) the 20- to 85-year age group and (C) the 35- to 64-year age group. Association between advanced fibrosis and all-cause mortality was analysed using survey-weighted multivariable Cox proportional models (adjusted for age, sex, race/ethnicity, BMI, alcohol and smoking status, and poverty). ALT, alanine aminotransferase; FIB-4, Fibrosis-4; HR, hazard ratio; NHANES, National Health and Nutrition Examination Survey; ULN, upper limit of normal.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><fig id="fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Time trends and prevalence of advanced liver fibrosis.</p><p>(A) The change in the number (millions) of US adults with advanced liver fibrosis (black) and fibrosis defined by FIB-4 &#8805;2.67 and/or Forns &#8805;6.9 (purple) overtime with 95% CIs (dashed). (B) Age-standardised weighted prevalence of advanced fibrosis (black) and fibrosis (purple) over time. Age-standardised weighted prevalence of advanced fibrosis in (C) people 20&#8211;85 years old and (D) people 35&#8211;64 years old (total, males, and females), stratified by race/ethnicity. Differences between groups were tested by univariate <italic toggle="yes">t</italic> statistics, &#8727;<italic toggle="yes">p</italic> &lt;0.05. FIB-4, Fibrosis-4; MA, Mexican American; NHB, non-Hispanic Black; NHW, non-Hispanic White; O, other race.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec3.2"><title>Associated conditions</title><p id="p0085">The age-standardised weighted prevalence of advanced LF was compared between people with and those without health conditions that might be considered as eligibility criteria in risk factor-based screening. Several conditions differed by race/ethnicity. The prevalence of advanced LF was about twofold higher in those with diabetes in the total population and in the NHW, MA, and O groups, but not in the NHB group (total, males, and females) (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref>A and <xref rid="appsec1" ref-type="sec">Figs.&#160;S1 and S2</xref>); similar results were obtained when alternative definitions of diabetes were used, underscoring the robustness of the finding (<xref rid="appsec1" ref-type="sec">Fig.&#160;S3</xref>). Only 35% (95% CI 29.9&#8211;40.1) of participants with advanced LF had diabetes, and thus, 65% of cases would be missed if screening were limited to people with diabetes. Associations between obesity and advanced LF also differed by race/ethnicity. The prevalence of fibrosis was significantly higher in the MA and O groups with obesity than in those with normal BMI (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref>C). Strikingly, however, among NHB persons, the prevalence was about twofold higher in those with <italic toggle="yes">normal</italic> BMI than in those with obesity, with similar results obtained for WC (<xref rid="appsec1" ref-type="sec">Fig.&#160;S4</xref>). Poverty was associated with advanced LF in NHB persons, but not in any other racial/ethnic group. Of the six conditions that reflect exposure to exogenous toxins, four (smoking, current excessive drinking, cadmium exposure, and lead exposure) were associated with advanced LF in the total population, in NHW persons, and in NHB persons (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref>F, I, K, and L). Former drinkers had a higher prevalence of advanced LF in NHB persons (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref>G). In sensitivity analyses, similar results were obtained when a less restrictive definition of LF (without the requirement for ALT elevation) was used (<xref rid="appsec1" ref-type="sec">Fig.&#160;S5</xref>).<fig id="fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Advanced fibrosis in participants aged 20&#8211;85 years, stratified by health conditions and race/ethnicity.</p><p>The age-standardised weighted prevalence of advanced fibrosis among participants with and those without various health conditions were determined for the total cohort, NHW, NHB, MA, and other racial/ethnic groups. (A) Diabetes, (B) hypertension, (C) BMI categories (N, OW, and OB), (D) metabolic syndrome, (E) kidney insufficiency, (F) current/past smokers, (G) former drinkers <italic toggle="yes">vs</italic>. lifetime abstainers, (H) current non-excessive drinkers <italic toggle="yes">vs</italic>. lifetime abstainers, (I) current excessive drinkers <italic toggle="yes">vs</italic>. lifetime abstainers, (J) poverty, and blood levels of (K) lead and (L) cadmium (Q1&#8211;Q3 <italic toggle="yes">vs</italic>. Q4). Differences between groups were tested by univariate <italic toggle="yes">t</italic> statistics, &#8727;<italic toggle="yes">p</italic> &lt;0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &lt;0.001, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt;0.0001. <sup>a</sup>Components of metabolic syndrome were only available for participants with fasting blood tests in NHANES 2007&#8211;2018 (n&#160;= 13,886). <sup>b</sup>Cadmium and lead analyses were based on participants with cadmium and lead measurements (N&#160;= 42,255). Red boxes marked variables whose association with advanced fibrosis differs qualitatively between NHW persons and members of all other race/ethnic groups. MA, Mexican American; N, normal; NHANES, National Health and Nutrition Examination Survey; NHB, non-Hispanic Black; NHW, non-Hispanic White; OB, obese; OW, overweight; Q1&#8211;Q4, quartiles 1&#8211;4.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec3.3"><title>Prevalence of risk factors</title><p id="p0090">Compared with NHW persons, NHB persons had a lower prevalence of smoking and excessive drinking; however, they had a higher prevalence of many other conditions, including diabetes. Thus, the disconnection between diabetes and advanced LF in NHB persons does not result from a low prevalence of diabetes. NHB persons also had a higher prevalence of KI, hypertension, obesity, poverty, and exposure to environmental pollutants, as indicated by higher blood levels of lead, cadmium, and PCBs (<xref rid="fig4" ref-type="fig">Fig.&#160;4</xref>). Both heavy metals and organic chemicals are associated with liver disease.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><fig id="fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Prevalence of heath conditions in participants aged 20&#8211;85 years, stratified by race/ethnicity.</p><p>Age-standardised weighted prevalence of (A) diabetes, (B) hypertension, (C) obesity (BMI &#8805;30&#160;kg/m<sup>2</sup>), (D) metabolic syndrome, (E) kidney insufficiency, (F) past/current smokers, (G) former drinker, (H) current non-excessive drinker, (I) current excessive drinker, (J) poverty, and Q4 blood level of (K) lead, (L) cadmium, and (M) total PCBs among NHW (blue), NHB (red), MA, and other race groups. <sup>a</sup>Components of metabolic syndrome were only available for participants with fasting blood test in NHANES 2007&#8211;2018 (N&#160;= 13,886). <sup>b</sup>Cadmium and lead analyses were based on participants with cadmium and lead measurements (N&#160;= 42,255). <sup>c</sup>PCB data from NHANES 2003&#8211;2004 survey cycles included 1,242 participants. Differences between groups were tested by univariate <italic toggle="yes">t</italic> statistics, &#8727;<italic toggle="yes">p</italic> &lt;0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &lt;0.001, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt;0.0001. Red boxes identified conditions more prevalent in NHB persons than in NHW persons; blue boxes identified the opposite. MA, Mexican American; NHANES, National Health and Nutrition Examination Survey; NHB, non-Hispanic Black; NHW, non-Hispanic White; PCB, polychlorinated biphenyl; Q4, quartile&#160;4.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec3.4"><title>Conditions independently associated with advanced LF</title><p id="p0095">Multivariable logistic regression was used to identify factors independently associated with advanced LF. Variables included age, sex, KI, diabetes, hypertension, BMI, alcohol use, smoking, and poverty. Two age groups were analysed (20&#8211;85 and 36&#8211;64 years). In the 20- to 85-year age group, smoking and current excessive drinking were risk factors in both NHW and NHB persons (<xref rid="tbl1" ref-type="table">Table&#160;1</xref>). Diabetes and hypertension were independently associated with advanced LF in NHW persons, but not in NHB persons. Conversely, poverty was a risk factor in NHB persons, but not in NHW persons.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table&#160;1</label><caption><p><bold>ORs from multivariable logistic regression models with the outcome of advanced liver fibrosis</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Cohorts<hr/></th><th colspan="5" rowspan="1">Cohort aged 20&#8211;85 years, OR (95% CI)<hr/></th></tr><tr><th colspan="1" rowspan="1">Sample size (n)</th><th colspan="1" rowspan="1">Total (47,442)</th><th colspan="1" rowspan="1">NHW (21,167)</th><th colspan="1" rowspan="1">NHB (9,634)</th><th colspan="1" rowspan="1">MA (8,334)</th><th colspan="1" rowspan="1">O (8,307)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Advanced fibrosis cases (n)</td><td colspan="1" rowspan="1"><bold>642</bold></td><td colspan="1" rowspan="1"><bold>259</bold></td><td colspan="1" rowspan="1"><bold>149</bold></td><td colspan="1" rowspan="1"><bold>127</bold></td><td colspan="1" rowspan="1"><bold>107</bold></td></tr><tr><td colspan="1" rowspan="1">Age (unit 10 years)</td><td colspan="1" rowspan="1"><bold>1.58 (1.47, 1.67)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.54 (1.40, 1.69)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.55 (1.36, 1.75)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.78 (1.49, 2.13)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.98 (1.70, 2.31)</bold><sup><bold>&#8225;</bold></sup></td></tr><tr><td colspan="1" rowspan="1">Sex</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td colspan="1" rowspan="1"><bold>1.44 (1.15, 1.87)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.47 (1.01, 2.13)&#8727;</bold></td><td colspan="1" rowspan="1">1.43 (0.99, 2.06)</td><td colspan="1" rowspan="1">1.19 (0.69, 2.05)</td><td colspan="1" rowspan="1">1.34 (0.81, 2.22)</td></tr><tr><td colspan="1" rowspan="1">Kidney insufficiency</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">1.30 (0.99, 1.71)</td><td colspan="1" rowspan="1">1.39 (0.94, 2.06)</td><td colspan="1" rowspan="1">1.00 (0.65, 1.54)</td><td colspan="1" rowspan="1">1.04 (0.57, 1.89)</td><td colspan="1" rowspan="1">1.47 (0.86, 2.54)</td></tr><tr><td colspan="1" rowspan="1">Diabetes</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1"><bold>2.23 (1.75, 2.84)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>2.58 (1.89, 3.52)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1">0.88 (0.61, 1.27)</td><td colspan="1" rowspan="1">1.65 (0.93, 2.91)</td><td colspan="1" rowspan="1"><bold>2.43 (1.33, 4.44)&#8727;</bold></td></tr><tr><td colspan="1" rowspan="1">Hypertension</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1"><bold>1.63 (1.21, 2.19)&#8727;</bold></td><td colspan="1" rowspan="1"><bold>1.70 (1.11, 2.59)&#8727;</bold></td><td colspan="1" rowspan="1">1.25 (0.80, 1.94)</td><td colspan="1" rowspan="1"><bold>2.03 (1.14, 3.61)&#8727;</bold></td><td colspan="1" rowspan="1">1.21 (0.65, 2.23)</td></tr><tr><td colspan="1" rowspan="1">BMI</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Normal</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Overweight</td><td colspan="1" rowspan="1">0.88 (0.63, 1.23)</td><td colspan="1" rowspan="1">0.81 (0.50, 1.32)</td><td colspan="1" rowspan="1">1.01 (0.61, 1.67)</td><td colspan="1" rowspan="1">1.33 (0.67, 2.68)</td><td colspan="1" rowspan="1">0.98 (0.57, 1.68)</td></tr><tr><td colspan="1" rowspan="1">&#160;Obese</td><td colspan="1" rowspan="1">0.93 (0.69, 1.27)</td><td colspan="1" rowspan="1">0.86 (0.56, 1.30)</td><td colspan="1" rowspan="1">0.68 (0.40, 1.14)</td><td colspan="1" rowspan="1">1.39 (0.67, 2.89)</td><td colspan="1" rowspan="1">1.74 (0.91, 3.32)</td></tr><tr><td colspan="1" rowspan="1">Alcohol use</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Lifetime abstainers</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Former drinkers</td><td colspan="1" rowspan="1">0.86 (0.60, 1.24)</td><td colspan="1" rowspan="1">0.84 (0.48, 1.46)</td><td colspan="1" rowspan="1">1.60 (0.87, 2.93)</td><td colspan="1" rowspan="1">0.96 (0.57, 1.63)</td><td colspan="1" rowspan="1">0.67 (0.31, 1.45)</td></tr><tr><td colspan="1" rowspan="1">&#160;Non-excessive current drinkers</td><td colspan="1" rowspan="1">0.93 (0.65, 1.33)</td><td colspan="1" rowspan="1">1.02 (0.59, 1.74)</td><td colspan="1" rowspan="1">1.38 (0.74, 2.58)</td><td colspan="1" rowspan="1">0.89 (0.58, 1.36)</td><td colspan="1" rowspan="1">0.57 (0.28, 1.16)</td></tr><tr><td colspan="1" rowspan="1">&#160;Excessive current drinkers</td><td colspan="1" rowspan="1"><bold>2.04 (1.38, 3.02)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1"><bold>2.17 (1.19, 3.95)&#8727;</bold></td><td colspan="1" rowspan="1"><bold>2.65 (1.48, 4.73)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1"><bold>2.36 (1.24, 4.49)&#8727;</bold></td><td colspan="1" rowspan="1">1.47 (0.70, 3.09)</td></tr><tr><td colspan="1" rowspan="1">Smoking status</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Never</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Past/current</td><td colspan="1" rowspan="1"><bold>1.68 (1.30, 2.16)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.67 (1.17, 2.36)&#8727;</bold></td><td colspan="1" rowspan="1"><bold>1.79 (1.21, 2.64)&#8727;</bold></td><td colspan="1" rowspan="1">1.41 (0.80, 2.47)</td><td colspan="1" rowspan="1"><bold>2.03 (1.09, 3.80)&#8727;</bold></td></tr><tr><td colspan="1" rowspan="1">Poverty</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1"><bold>1.49 (1.19, 1.87)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1">1.25 (0.84, 1.87)</td><td colspan="1" rowspan="1"><bold>2.09 (1.44, 3.03)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1">1.16 (0.69, 1.96)</td><td colspan="1" rowspan="1">1.13 (0.75, 1.71)</td></tr></tbody></table><table-wrap-foot><fn><p>Multiple imputation was performed in univariate and multivariate logistic regression models. Variables with a <italic toggle="yes">p</italic> value of &lt;0.1 in the univariate analysis in the total cohort were included into the multivariate analysis. &#8727;<italic toggle="yes">p</italic> &lt;0.05, <sup>&#8224;</sup><italic toggle="yes">p</italic> &lt;0.001, <sup>&#8225;</sup><italic toggle="yes">p</italic> &lt;0.0001. The significant variables were labeled as bold front. MA, Mexican American; NHB, non-Hispanic Black; NHW, non-Hispanic White; O, other race; OR, odds ratio.</p></fn></table-wrap-foot></table-wrap></p><p id="p0100">Six sensitivity analyses were conducted to confirm the robustness of the associations between the independent variables in <xref rid="tbl1" ref-type="table">Table&#160;1</xref> and advanced LF: (1) In a sensitivity analysis that excluded participants with VH, generally similar odds ratios (ORs) obtained. Among NHB persons, the OR for diabetes was 0.76 (95% CI 0.39&#8211;1.48), and the OR for smoking was 3.00 (95% CI 1.56&#8211;5.78) (<xref rid="appsec1" ref-type="sec">Table&#160;S2</xref>). (2) Similarly, when participants with ALD (defined in the Materials and methods section) were excluded, diabetes was not significantly associated with advanced LF among NHB persons (OR 1.01; 95% CI 0.64&#8211;1.59), whereas poverty remained a risk factor (OR 2.10; 95% CI 1.29&#8211;3.42) (<xref rid="appsec1" ref-type="sec">Table&#160;S3</xref>). (3) When metabolic syndrome was substituted for diabetes, hypertension, and obesity, it was associated with advanced LF in the total group (<xref rid="appsec1" ref-type="sec">Table&#160;S4</xref>). (4) In an analysis of the 35- to 64-year age group, results were generally similar to those of the 20- to 85-year age group; however, in the 35- to 64-year age group, KI was a risk factor for advanced LF in NHW persons, and poverty was a risk factor in NHW persons, as well as in NHB persons (<xref rid="appsec1" ref-type="sec">Table&#160;S5</xref>). (5) KI was an independent risk factor in all racial/ethnic groups in a sensitivity analysis that used the less restrictive definition of LF (<xref rid="appsec1" ref-type="sec">Table&#160;S6</xref>). (6) Finally, when FIB-4 &#8805;3.25, which has an overall accuracy of 86% in predicting advanced fibrosis,<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> was used as the dependent variable, results were similar to those in <xref rid="tbl1" ref-type="table">Table&#160;1</xref>. Among NHB persons, the OR for diabetes was 0.74 (95% CI 0.51&#8211;1.08), whereas poverty and excessive alcohol use were strongly associated with FIB-4 &#8805;3.25 (<xref rid="appsec1" ref-type="sec">Table&#160;S7</xref>).</p></sec><sec id="sec3.5"><title>Environmental exposures and advanced LF</title><p id="p0105">High blood levels of cadmium, as indicated by measurements in Q4, were associated with advanced LF in the total population and in NHW, NHB, and MA persons in multivariable logistic regression analysis (<xref rid="tbl2" ref-type="table">Table&#160;2</xref>). Blood levels of lead were strongly associated with advanced LF in NHB persons, but not significantly associated with advanced LF in NHW persons: OR 3.25 (95% CI 1.95&#8211;5.43) <italic toggle="yes">vs</italic>. OR 1.24 (95% CI 0.79&#8211;1.94; <italic toggle="yes">p</italic>&#160;= 0.34) (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>). Associations between advanced LF and heavy metal exposures were dose dependent for both cadmium and lead (<xref rid="appsec1" ref-type="sec">Tables&#160;S8 and S9</xref>, respectively). Results were similar in sensitivity analysis in which participants with VH were excluded (<xref rid="appsec1" ref-type="sec">Tables&#160;S10 and S11</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table&#160;2</label><caption><p><bold>ORs from multivariable logistic regression models with the outcome of advanced liver fibrosis with blood cadmium levels included in the models</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Cohorts<hr/></th><th colspan="5" rowspan="1">In participants aged 20&#8211;85 years with cadmium into models, OR (95% CI)<hr/></th></tr><tr><th colspan="1" rowspan="1">Sample size (n)</th><th colspan="1" rowspan="1">Total (42,255)</th><th colspan="1" rowspan="1">NHW (19,176)</th><th colspan="1" rowspan="1">NHB (8,585)</th><th colspan="1" rowspan="1">MA (7,508)</th><th colspan="1" rowspan="1">O (6,986)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Advanced fibrosis cases (n)</td><td colspan="1" rowspan="1"><bold>542</bold></td><td colspan="1" rowspan="1"><bold>226</bold></td><td colspan="1" rowspan="1"><bold>128</bold></td><td colspan="1" rowspan="1"><bold>102</bold></td><td colspan="1" rowspan="1"><bold>86</bold></td></tr><tr><td colspan="1" rowspan="1">Survey year</td><td colspan="1" rowspan="1"><bold>1.07 (1.03, 1.11)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.08 (1.03, 1.13)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1">1.01 (0.95, 1.08)</td><td colspan="1" rowspan="1">1.10 (0.99, 1.20)</td><td colspan="1" rowspan="1">1.03 (0.94, 1.13)</td></tr><tr><td colspan="1" rowspan="1">Age (unit 10 years)</td><td colspan="1" rowspan="1"><bold>1.56 (1.44, 1.68)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.51 (1.36, 1.69)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.52 (1.31, 1.76)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.79 (1.46, 2.21)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>2.09 (1.75, 2.50)</bold><sup><bold>&#8225;</bold></sup></td></tr><tr><td colspan="1" rowspan="1">Sex</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td colspan="1" rowspan="1"><bold>1.61 (1.24, 2.08)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.67 (1.16, 2.41)</bold>&#8727;</td><td colspan="1" rowspan="1"><bold>1.61 (1.08, 2.40)&#8727;</bold></td><td colspan="1" rowspan="1">1.30 (0.71, 2.36)</td><td colspan="1" rowspan="1">1.25 (0.65, 2.40)</td></tr><tr><td colspan="1" rowspan="1">Kidney insufficiency</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">1.15 (0.85, 1.55)</td><td colspan="1" rowspan="1">1.16 (0.75, 1.79)</td><td colspan="1" rowspan="1">1.17 (0.74, 1.84)</td><td colspan="1" rowspan="1"><bold>0.58 (0.36, 0.94)</bold>&#8727;</td><td colspan="1" rowspan="1">1.54 (0.83, 2.87)</td></tr><tr><td colspan="1" rowspan="1">Diabetes</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1"><bold>2.38 (1.83, 3.11)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>2.85 (2.05, 3.96)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1">0.78 (0.50, 1.19)</td><td colspan="1" rowspan="1"><bold>1.97 (1.04, 3.73)</bold>&#8727;</td><td colspan="1" rowspan="1"><bold>2.60 (1.26, 5.35)&#8727;</bold></td></tr><tr><td colspan="1" rowspan="1">Hypertension</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1"><bold>1.86 (1.33, 2.58)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1"><bold>2.04 (1.27, 3.27)</bold>&#8727;</td><td colspan="1" rowspan="1">1.32 (0.77, 2.24)</td><td colspan="1" rowspan="1"><bold>2.37 (1.15, 4.86)</bold>&#8727;</td><td colspan="1" rowspan="1">1.13 (0.54, 2.35)</td></tr><tr><td colspan="1" rowspan="1">BMI</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Normal</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Overweight</td><td colspan="1" rowspan="1">0.89 (0.60, 1.33)</td><td colspan="1" rowspan="1">0.85 (0.48, 1.49)</td><td colspan="1" rowspan="1">0.91 (0.52, 1.57)</td><td colspan="1" rowspan="1">1.15 (0.56, 2.34)</td><td colspan="1" rowspan="1">0.94 (0.43, 2.08)</td></tr><tr><td colspan="1" rowspan="1">&#160;Obese</td><td colspan="1" rowspan="1">0.92 (0.64, 1.32)</td><td colspan="1" rowspan="1">0.81 (0.49, 1.33)</td><td colspan="1" rowspan="1">0.80 (0.47, 1.39)</td><td colspan="1" rowspan="1">1.02 (0.46, 2.30)</td><td colspan="1" rowspan="1">2.00 (0.83, 4.85)</td></tr><tr><td colspan="1" rowspan="1">Alcohol use</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Lifetime abstainers</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Former drinkers</td><td colspan="1" rowspan="1">0.92 (0.61, 1.38)</td><td colspan="1" rowspan="1">0.85 (0.49, 1.47)</td><td colspan="1" rowspan="1">1.91 (0.86, 4.25)</td><td colspan="1" rowspan="1">0.84 (0.30, 2.35)</td><td colspan="1" rowspan="1">0.87 (0.33, 2.29)</td></tr><tr><td colspan="1" rowspan="1">&#160;Non-excessive current drinkers</td><td colspan="1" rowspan="1">1.00 (0.66, 1.52)</td><td colspan="1" rowspan="1">1.06 (0.61, 1.85)</td><td colspan="1" rowspan="1">1.41 (0.59, 3.34)</td><td colspan="1" rowspan="1">0.81 (0.26, 2.50)</td><td colspan="1" rowspan="1">0.74 (0.30, 1.82)</td></tr><tr><td colspan="1" rowspan="1">&#160;Excessive current drinkers</td><td colspan="1" rowspan="1"><bold>2.02 (1.30, 3.13)&#8727;</bold></td><td colspan="1" rowspan="1"><bold>2.08 (1.12, 3.85)&#8727;</bold></td><td colspan="1" rowspan="1"><bold>2.65 (1.19, 5.90)&#8727;</bold></td><td colspan="1" rowspan="1">2.03 (0.63, 6.46)</td><td colspan="1" rowspan="1">1.70 (0.64, 4.57)</td></tr><tr><td colspan="1" rowspan="1">Smoking status</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Never</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Past/current</td><td colspan="1" rowspan="1"><bold>1.40 (1.03, 1.91)&#8727;</bold></td><td colspan="1" rowspan="1">1.42 (0.94, 2.14)</td><td colspan="1" rowspan="1">1.23 (0.76, 2.00)</td><td colspan="1" rowspan="1">1.37 (0.67, 2.80)</td><td colspan="1" rowspan="1">1.71 (0.72, 4.06)</td></tr><tr><td colspan="1" rowspan="1">Poverty</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1"><bold>1.36 (1.02, 1.80)&#8727;</bold></td><td colspan="1" rowspan="1">1.00 (0.62, 1.62)</td><td colspan="1" rowspan="1"><bold>1.95 (1.26, 3.02)&#8727;</bold></td><td colspan="1" rowspan="1">1.11 (0.57, 2.19)</td><td colspan="1" rowspan="1">1.06 (0.56, 2.01)</td></tr><tr><td colspan="1" rowspan="1">Blood cadmium level</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Q1&#8211;Q3</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Q4</td><td colspan="1" rowspan="1"><bold>1.81 (1.30, 2.53)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.75 (1.08, 2.85)&#8727;</bold></td><td colspan="1" rowspan="1"><bold>2.01 (1.23, 3.30)&#8727;</bold></td><td colspan="1" rowspan="1"><bold>2.24 (1.21, 4.16)&#8727;</bold></td><td colspan="1" rowspan="1">1.75 (0.83, 3.65)</td></tr></tbody></table><table-wrap-foot><fn><p>Cadmium analysis based on participants with information of blood lead and cadmium measurements (N&#160;= 42,255). Multiple imputation was performed in univariate and multivariate logistic regression models. Variables with a <italic toggle="yes">p</italic> value of &lt;0.1 in the univariate analysis in the total cohort were included into the multivariate analysis. &#8727;<italic toggle="yes">p</italic> &lt;0.05, <sup>&#8224;</sup><italic toggle="yes">p</italic> &lt; 0.001, <sup>&#8225;</sup><italic toggle="yes">p</italic> &lt;0.0001. The significant variables were labeled as bold front. MA, Mexican American; NHB, non-Hispanic Black; NHW, non-Hispanic White; O, other race; OR, odds ratio; Q1&#8211;Q4, quartiles 1&#8211;4.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table&#160;3</label><caption><p><bold>ORs from multivariable logistic regression models with the outcome of advanced liver fibrosis with blood lead levels included in the models</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Cohorts<hr/></th><th colspan="5" rowspan="1">In participants aged 20&#8211;85 years with blood lead level into models, OR (95% CI)<hr/></th></tr><tr><th colspan="1" rowspan="1">Sample size (n)</th><th colspan="1" rowspan="1">Total (42,255)</th><th colspan="1" rowspan="1">NHW (19,176)</th><th colspan="1" rowspan="1">NHB (8,585)</th><th colspan="1" rowspan="1">MA (7,508)</th><th colspan="1" rowspan="1">O (6,986)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Advanced fibrosis cases (n)</td><td colspan="1" rowspan="1"><bold>542</bold></td><td colspan="1" rowspan="1"><bold>226</bold></td><td colspan="1" rowspan="1"><bold>128</bold></td><td colspan="1" rowspan="1"><bold>102</bold></td><td colspan="1" rowspan="1"><bold>86</bold></td></tr><tr><td colspan="1" rowspan="1">Survey year</td><td colspan="1" rowspan="1"><bold>1.08 (1.04, 1.12)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.09 (1.04, 1.14)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.07 (1.01, 1.14)</bold>&#8727;</td><td colspan="1" rowspan="1">1.06 (0.97, 1.17)</td><td colspan="1" rowspan="1">1.02 (0.92, 1.12)</td></tr><tr><td colspan="1" rowspan="1">Age (unit 10 years)</td><td colspan="1" rowspan="1"><bold>1.52 (1.40, 1.65)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.47 (1.31, 1.66)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.35 (1.16, 1.59)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.83 (1.49, 2.26)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>2.12 (1.78, 2.53)</bold><sup><bold>&#8225;</bold></sup></td></tr><tr><td colspan="1" rowspan="1">Sex</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td colspan="1" rowspan="1"><bold>1.46 (1.11, 1.92)</bold>&#8727;</td><td colspan="1" rowspan="1"><bold>1.54 (1.04, 2.28)</bold>&#8727;</td><td colspan="1" rowspan="1">1.12 (0.72, 1.74)</td><td colspan="1" rowspan="1">1.24 (0.69, 2.22)</td><td colspan="1" rowspan="1">1.19 (0.67, 2.14)</td></tr><tr><td colspan="1" rowspan="1">Kidney insufficiency</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">1.19 (0.88, 1.59)</td><td colspan="1" rowspan="1">1.20 (0.79, 1.84)</td><td colspan="1" rowspan="1">1.01 (0.46, 2.24)</td><td colspan="1" rowspan="1">0.63 (0.38, 1.05)</td><td colspan="1" rowspan="1">1.58 (0.85, 2.93)</td></tr><tr><td colspan="1" rowspan="1">Diabetes</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1"><bold>2.37 (1.82, 3.10)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1"><bold>2.84 (2.04, 3.95)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1">0.82 (0.53, 1.26)</td><td colspan="1" rowspan="1">1.85 (0.99, 3.44)</td><td colspan="1" rowspan="1"><bold>2.56 (1.27, 5.14)</bold><sup><bold>&#8224;</bold></sup></td></tr><tr><td colspan="1" rowspan="1">Hypertension</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1"><bold>1.87 (1.34, 2.60)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1"><bold>2.04 (1.27, 3.29)</bold>&#8727;</td><td colspan="1" rowspan="1">1.29 (0.76, 2.20)</td><td colspan="1" rowspan="1"><bold>2.38 (1.16, 4.89)</bold>&#8727;</td><td colspan="1" rowspan="1">1.12 (0.53, 2.35)</td></tr><tr><td colspan="1" rowspan="1">BMI</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Normal</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Overweight</td><td colspan="1" rowspan="1">0.85 (0.58, 1.25)</td><td colspan="1" rowspan="1">0.81 (0.47, 1.42)</td><td colspan="1" rowspan="1">0.89 (0.51, 1.56)</td><td colspan="1" rowspan="1">1.08 (0.51, 2.28)</td><td colspan="1" rowspan="1">0.87 (0.41, 1.87)</td></tr><tr><td colspan="1" rowspan="1">&#160;Obese</td><td colspan="1" rowspan="1">0.86 (0.61, 1.21)</td><td colspan="1" rowspan="1">0.76 (0.47, 1.22)</td><td colspan="1" rowspan="1">0.83 (0.48, 1.44)</td><td colspan="1" rowspan="1">0.93 (0.42, 2.09)</td><td colspan="1" rowspan="1">1.73 (0.70, 4.27)</td></tr><tr><td colspan="1" rowspan="1">Alcohol use</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Lifetime abstainers</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Former drinkers</td><td colspan="1" rowspan="1">0.91 (0.61, 1.37)</td><td colspan="1" rowspan="1">0.87 (0.50, 1.50)</td><td colspan="1" rowspan="1">1.72 (0.77, 3.87)</td><td colspan="1" rowspan="1">0.84 (0.30, 2.30)</td><td colspan="1" rowspan="1">0.86 (0.34, 2.14)</td></tr><tr><td colspan="1" rowspan="1">&#160;Non-excessive current drinkers</td><td colspan="1" rowspan="1">0.97 (0.64, 1.46)</td><td colspan="1" rowspan="1">1.05 (0.61, 1.81)</td><td colspan="1" rowspan="1">1.33 (0.56, 3.14)</td><td colspan="1" rowspan="1">0.78 (0.25, 2.41)</td><td colspan="1" rowspan="1">0.75 (0.31, 1.77)</td></tr><tr><td colspan="1" rowspan="1">&#160;Excessive current drinkers</td><td colspan="1" rowspan="1"><bold>1.96 (1.26, 3.05)</bold>&#8727;</td><td colspan="1" rowspan="1"><bold>2.05 (1.10, 3.81)</bold>&#8727;</td><td colspan="1" rowspan="1"><bold>2.38 (1.08, 5.25)</bold>&#8727;</td><td colspan="1" rowspan="1">2.07 (0.65, 6.55)</td><td colspan="1" rowspan="1">1.71 (0.66, 4.43)</td></tr><tr><td colspan="1" rowspan="1">Smoking status</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Never</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Past/current</td><td colspan="1" rowspan="1"><bold>1.68 (1.27, 2.22)</bold><sup><bold>&#8224;</bold></sup></td><td colspan="1" rowspan="1"><bold>1.68 (1.15, 2.45)</bold>&#8727;</td><td colspan="1" rowspan="1">1.44 (0.92, 2.25)</td><td colspan="1" rowspan="1">1.75 (0.92, 3.33)</td><td colspan="1" rowspan="1">1.96 (0.90, 4.24)</td></tr><tr><td colspan="1" rowspan="1">Poverty</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1"><bold>1.36 (1.02, 1.80)</bold>&#8727;</td><td colspan="1" rowspan="1">1.07 (0.66, 1.73)</td><td colspan="1" rowspan="1"><bold>1.86 (1.19, 2.90)</bold>&#8727;</td><td colspan="1" rowspan="1">1.21 (0.64, 2.31)</td><td colspan="1" rowspan="1">1.10 (0.59, 2.06)</td></tr><tr><td colspan="1" rowspan="1">Blood lead level</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Q1&#8211;Q3</td><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1">Reference</td></tr><tr><td colspan="1" rowspan="1">&#160;Q4</td><td colspan="1" rowspan="1">1.32 (0.96, 1.80)</td><td colspan="1" rowspan="1">1.24 (0.79, 1.94)</td><td colspan="1" rowspan="1"><bold>3.25 (1.95, 5.43)</bold><sup><bold>&#8225;</bold></sup></td><td colspan="1" rowspan="1">0.72 (0.40, 1.28)</td><td colspan="1" rowspan="1">0.84 (0.39, 1.83)</td></tr></tbody></table><table-wrap-foot><fn><p>Lead analysis based on participants with information of blood lead and cadmium measurements (N&#160;= 42,255). Multiple imputation was performed in univariate and multivariate logistic regression models. Variables with a <italic toggle="yes">p</italic> value of &lt;0.1 in the univariate analysis in the total cohort were included into the multivariate analysis. &#8727;<italic toggle="yes">p</italic> &lt;0.05, <sup>&#8224;</sup><italic toggle="yes">p</italic> &lt;0.001, <sup>&#8225;</sup><italic toggle="yes">p</italic> &lt;0.0001. The significant variables were labeled as bold front. MA, Mexican American; NHB, non-Hispanic Black; NHW, non-Hispanic White; O, other race; OR, odds ratio; Q1&#8211;Q4, quartiles 1&#8211;4.</p></fn></table-wrap-foot></table-wrap></p><p id="p0110">NHANES 2003&#8211;2004 measured lipid-adjusted plasma levels of PCBs in 1,242 adults (<xref rid="appsec1" ref-type="sec">Fig.&#160;S6</xref>). Over 95% of the participants with advanced LF had high PCB exposure (<xref rid="fig5" ref-type="fig">Fig.&#160;5</xref>). The small sample size precluded an analysis by race/ethnicity.<fig id="fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Association between advanced fibrosis and PCBs (NHANES 2003&#8211;2004).</p><p>(A) Age-standardised weighted prevalence of advanced liver fibrosis in people with low (Q1&#8211;Q3) and high (Q4) lipid-adjusted plasma measurements of total PCBs in participants in NHANES 2003&#8211;2004. (B) Distribution of advanced fibrosis cases in participants with Q1&#8211;Q3 (white) <italic toggle="yes">vs</italic>. Q4 (dotted) levels of total PCBs. Differences between groups were tested by univariate <italic toggle="yes">t</italic> statistics, &#8727;<italic toggle="yes">p</italic> &lt;0.05, and by logistic regression with age adjustment, <italic toggle="yes">p</italic>&#160;= 0.0001. NHANES, National Health and Nutrition Examination Survey; PCB, polychlorinated biphenyl; Q1&#8211;Q4, quartiles 1&#8211;4.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec><sec id="sec3.6"><title>Time trends of health conditions from 1999&#8211;2000 to 2017&#8211;2018</title><p id="p0115">To identify factors that might underlie the increase in advanced LF and to determine whether the 8.7% APC was typical of other diseases, we examined time trends for 13 other conditions (<xref rid="appsec1" ref-type="sec">Table&#160;S1</xref>). The age-standardised weighted prevalence of high lead and cadmium exposure decreased, as did the percentage of former drinkers in the total population, in NHW persons, and in NHB persons. Smoking decreased in the total population, but the decrease was not significant among NHB persons. KI, hypertension, and current non-excessive drinking did not change significantly. Diabetes increased 1.6-fold in the total population (APC 4.9%) and in all groups except the NHB group. Obesity, as defined by either BMI or WC, increased; however, obesity was not associated with advanced LF in multivariable logistic regression analyses. LF without the requirement for ALT elevation increased 2.0-fold in the total population (APC 10.7%), suggesting that advanced LF may continue to rise in the future (<xref rid="appsec1" ref-type="sec">Table&#160;S1</xref>). Current excessive drinking increased significantly in the total population (APC 2.3%) and increased 1.8-fold in NHB persons (APC 5.8%), underscoring the importance of alcohol in LF.</p></sec><sec id="sec3.7"><title>Fibrosis in adults with NEI</title><p id="p0120">Screening is often used to detect patients who have <italic toggle="yes">specific</italic> liver diseases. We investigated the percentage of people with advanced LF who might be missed if the population were screened for the three major liver diseases (namely, VH, ALD, and NAFLD), rather than for fibrosis. One analysis used the USFLI to define NAFLD (n&#160;= 20,388). The weighted prevalence of VH was 6.1% (95% CI 5.6&#8211;6.6%), that of ALD was 28.8% (95% CI, 27.8&#8211;29.8%), that of NAFLD was 18.7% (95% CI 17.8&#8211;19.5%), and that of the NEI category was 46.4% (95% CI 45.4&#8211;47.4%). Among the 285 participants with advanced LF, 36 (12.8%, 95% CI 7.5&#8211;18.0) did not meet criteria for VH, ALD, or NAFLD. A second analysis used ultrasound to define NAFLD (n&#160;= 12,811 NHANES III participants). Among the 84 participants with advanced LF, 10 (13.9%, 95% CI 3.6&#8211;24.2) did not meet criteria for VH, ALD, or NAFLD (<xref rid="appsec1" ref-type="sec">Figs.&#160;S7 and S8</xref>). In sensitivity analyses that used LF without the requirement for ALT elevation, almost 40% of the cases were in the NEI category (<xref rid="appsec1" ref-type="sec">Figs.&#160;S9 and S10</xref>). This corresponds to 3.24 million US adults averaged over the period analysed. Multivariable logistic regression identified KI as a risk factor for LF in the NEI category (<xref rid="appsec1" ref-type="sec">Table&#160;S12</xref>). These findings suggest that a significant percentage of advanced LF occurs in individuals who could be missed in aetiology-based screening programmes.</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0125">This study used nationally representative data to evaluate dynamic changes in the prevalence of advanced LF and to identify risk factors in the multi-ethnic US population. The results provide valuable information for the design of liver disease screening programmes. The study had three major findings.</p><p id="p0130">First, during the past 20 years, the prevalence of advanced LF approximately doubled and increased more rapidly than that of 13 other conditions. The number of people with advanced LF increased nearly threefold, reaching about 3.5 million in the 2017&#8211;2018 NHANES cycle. Liver care services will need to expand to care for these patients. Only diabetes increased more than 1.5-fold in the total population (APC 4.9%), which makes the increase in advanced LF (APC 8.7%) especially noteworthy. Although diabetes rose among NHW persons, it did not increase significantly in NHB persons. Conversely, current excessive drinking increased 1.8-fold (APC 5.8%) among NHB persons and may be an important driver. Excessive current drinking increased about 1.2-fold in the total population (APC 2.3%), underscoring the need to reduce harmful drinking.</p><p id="p0135">Second, advanced LF was strongly associated with heavy metal (lead and cadmium) exposure, and over 95% of participants with advanced LF had high lipid-adjusted levels of PCBs. These findings add to published data<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref> and should prompt a more extensive examination of toxic exposures in liver disease. Importantly, the World Health Organization classifies cadmium as a known human carcinogen.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> Additional factors independently associated with advanced LF were older age, male sex, diabetes, hypertension, excessive current drinking, past/current smoking, and poverty. KI was independently associated with advanced LF in the 35- to 64-year age group, consistent with previous reports.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> The association between LF and KI may reflect the shared roles of the liver and kidney in metabolism, detoxification, and excretion.</p><p id="p0140">Third, NHB persons (both men and women) had a higher prevalence of advanced LF than their NHW counterparts and different risk factors. These results add to past evidence that NHB persons have a distinctive pattern of liver disease presentation and genomic risk factors.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr">[38]</xref>, <xref rid="bib39" ref-type="bibr">[39]</xref>, <xref rid="bib40" ref-type="bibr">[40]</xref> A previous analysis of NHANES data also showed that NHB persons have a higher prevalence of cirrhosis,<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> although other studies reported a lower prevalence of biopsy-defined advanced LF among NHB persons.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Because NHB persons are often under-represented in clinical trials,<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> and may have incomplete medical records and less access to healthcare,<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> nationally representative data, as provided by NHANES, are especially important. Diabetes was independently associated with advanced LF in NHW<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> and O persons, but not in NHB persons, as shown before,<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> or in MA persons, which is consistent with published data, as past studies did not adjust for hypertension and KI.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> Among NHB persons, high blood levels of lead were strongly associated with advanced LF (OR 3.25), and poverty was also a risk factor. Poverty is associated with workplace and environmental toxic exposures.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> High blood levels of PCBs were strongly associated with advanced LF, and NHB persons had higher blood levels than NHW persons. Compared with NHW persons, NHB persons have a higher prevalence of a polymorphism in the gene encoding arylsulfatase A, a metabolic regulator<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> associated with lead-mediated neurotoxicity,<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> and they develop lung cancer at younger ages and with fewer pack-years of smoking,<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> suggesting that they may be especially vulnerable to toxic injury. In this study, NHB persons had a higher prevalence of KI, hypertension, obesity, poverty, and exposure to environmental pollutants (lead, cadmium, and PCB). These disparities could be associated with their reduced longevity.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref></p><p id="p0145">The study provided intriguing evidence that even if everyone in the United States were fully screened for VH, ALD, and NAFLD, 12&#8211;40% of significant LF might be missed. These findings are consistent with data showing that about 20% of cirrhosis-related deaths occur in people without any of the major liver diseases,<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> and with results showing that liver disease aetiology was unspecified in 48% of cirrhosis- or hepatocellular carcinoma-related deaths in the United States.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> These findings highlight the advantage of universal screening for advanced LF. At a negligible cost, electronic health records could flag patients with FIB-4 &#8805;2.67 and/or Forns &#8805;6.9 and ALT &#8805;ULN, providing a realistic backstop to risk factor-based and aetiology-based screening and offering a safety net for the high percentage of people without diabetes whose liver disease has not been diagnosed.</p><sec id="sec4.1"><title>Limitations</title><p id="p0150">The main limitations of this study are as follows: (1) the use of NHANES data, which are collected cross-sectionally at a single time point and are restricted to the housed noninstitutionalised population; (2) the use of the FIB-4/Forns scores and USFLI to define LF and NAFLD, rather than histopathology; and (3) the use of self-reported data to define race/ethnicity, alcohol use, and smoking habits. The study could not assess causality. To mitigate these limitations, we (1) acknowledge them here; (2) performed weighted and age-standardised analyses, which adjust for changes in the age and demographic structure of the population; and (3) used ultrasound to define NAFLD in confirmatory studies.</p></sec><sec id="sec4.2"><title>Conclusions</title><p id="p0155">In the United States, the prevalence of advanced LF doubled over the past 20 years and was higher in NHB persons (total group and men and women) than in NHW persons (total group and men and women). Liver care services will need to expand to meet the increased liver disease burden. Toxic exposures had especially strong associations with LF in NHB persons, suggesting that NHB persons may be particularly vulnerable. Poverty, smoking, excessive drinking, and exposure to environmental toxins are potentially modifiable LF risk factors. Universal screening with FIB-4 &#8805;2.67 and/or Forns &#8805;6.9 and ALT &#8805;ULN would be a realistic backstop to risk factor-based screening.</p></sec></sec><sec id="sec5"><title>Financial support</title><p id="p0160">This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000125</institution-id><institution>National Institute for Occupational Safety and Health</institution></institution-wrap></funding-source> (NIOSH): U01 OH01163 and the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100001299</institution-id><institution>Prevent Cancer Foundation</institution></institution-wrap></funding-source> (PCF 604934).</p></sec><sec id="sec6"><title>Authors&#8217; contributions</title><p id="p0175">Formal analysis: NM, RY. Methodology: NM, RY, SL, AD, CW, MC, AJ, LL, CA, MBB, DD, BW, DY, CH, ADB. Funding acquisition: ADB. Manuscript draft: NM, ADB. Manuscript review and editing: all authors.</p></sec><sec sec-type="data-availability" id="sec7"><title>Data availability statement</title><p id="p0180">The data that support the findings of this study are openly available at the National Health and Nutrition Examination Survey website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwn.cdc.gov/nchs/nhanes/Default.aspx" id="intref0015">https://wwwn.cdc.gov/nchs/nhanes/Default.aspx</ext-link>).</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p id="p0165">All authors declare no relevant or material financial interests that relate to the research described in this paper.</p><p id="p0170">Please refer to the accompanying ICMJE disclosure forms for further details.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Asrani</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Devarbhavi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>P.S.</given-names></name></person-group><article-title>Burden of liver diseases in the world</article-title><source>J&#160;Hepatol</source><volume>70</volume><year>2019</year><fpage>151</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">30266282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2018.09.014</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Schreiner</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Marsden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>S.</given-names></name><etal/></person-group><article-title>FIB-4 and incident severe liver outcomes in patients with undiagnosed chronic liver disease: a Fine&#8211;Gray competing risk analysis</article-title><source>Liver Int</source><volume>43</volume><year>2023</year><fpage>170</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">35567761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15295</pub-id><pub-id pub-id-type="pmcid">PMC9659674</pub-id></element-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="other" id="sref3">OHID. Guidance of Liver disease: applying All Our Health. Office for Health&#160;Improvement and Disparities (OHID) in England. Accessed date: 6&#160;May 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/liver-disease-applying-all-our-health/liver-disease-applying-all-our-health" id="intref0025">https://www.gov.uk/government/publications/liver-disease-applying-all-our-health/liver-disease-applying-all-our-health</ext-link>.</mixed-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Unalp-Arida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruhl</surname><given-names>C.E.</given-names></name></person-group><article-title>Liver fibrosis scores predict liver disease mortality in the United States population</article-title><source>Hepatology</source><volume>66</volume><year>2017</year><fpage>84</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">28195363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.29113</pub-id><pub-id pub-id-type="pmcid">PMC7005915</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Kanwal</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shubrook</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Pfotenhauer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wai-Sun Wong</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease</article-title><source>Gastroenterology</source><volume>161</volume><year>2021</year><fpage>1657</fpage><lpage>1669</lpage><pub-id pub-id-type="pmid">34602251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2021.07.049</pub-id><pub-id pub-id-type="pmcid">PMC8819923</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Hagstr&#246;m</surname><given-names>H.</given-names></name><name name-style="western"><surname>Talb&#228;ck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walldius</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hammar</surname><given-names>N.</given-names></name></person-group><article-title>Ability&#160;of&#160;noninvasive scoring systems to identify individuals in the population at risk for severe liver disease</article-title><source>Gastroenterology</source><volume>158</volume><year>2020</year><fpage>200</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">31563624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2019.09.008</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Sripongpun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Mannalithara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Charu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vidovszky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Asch</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care</article-title><source>Hepatology</source><volume>77</volume><year>2023</year><fpage>256</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">35477908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.32545</pub-id><pub-id pub-id-type="pmcid">PMC9613815</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Eskridge W, Vierling JM</surname></name><name name-style="western"><surname>Gosbee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Hyunh</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.E.</given-names></name></person-group><article-title>Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a population-based risk factor assessment using vibration controlled transient elastography (VCTE)</article-title><source>PLoS One</source><volume>16</volume><year>2021</year><object-id pub-id-type="publisher-id">e0260320</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0260320</pub-id><pub-id pub-id-type="pmcid">PMC8631660</pub-id><pub-id pub-id-type="pmid">34847156</pub-id></element-citation></ref><ref id="bib9"><label>9</label><mixed-citation publication-type="other" id="sref9">AASLD. Guidelines and Guidances in Development, Practice Guidelines: Non-Invasive Liver Disease Assessment. Accessed date June 1st, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.aasld.org/practice-guidelines" id="intref0030">https://www.aasld.org/practice-guidelines</ext-link>.</mixed-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis &#8211; 2021 update</article-title><source>J&#160;Hepatol</source><volume>75</volume><year>2021</year><fpage>659</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">34166721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2021.05.025</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Paulose-Ram</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ogden</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Kruszon-Moran</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dohrmann</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>National health and nutrition examination survey: analytic guidelines, 1999&#8211;2010</article-title><source>Vital Health Stat</source><volume>2</volume><year>2013</year><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">25090154</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="book" id="sref12"><person-group person-group-type="author"><collab>NCHS Data Linkage</collab></person-group><part-title>Public-use linked mortality files</part-title><year>2019</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/data-linkage/mortality-public.htm" id="intref0035">https://www.cdc.gov/nchs/data-linkage/mortality-public.htm</ext-link><comment>Accessed date May 30 2020</comment></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>McPherson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dufour</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Petta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Romero-Gomez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis</article-title><source>Am J Gastroenterol</source><volume>112</volume><year>2017</year><fpage>740</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">27725647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2016.453</pub-id><pub-id pub-id-type="pmcid">PMC5418560</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Inker</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Eneanya</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tighiouart</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>New creatinine- and cystatin C-based equations to estimate GFR without race</article-title><source>N&#160;Engl J Med</source><volume>385</volume><year>2021</year><fpage>1737</fpage><lpage>1749</lpage><pub-id pub-id-type="pmid">34554658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102953</pub-id><pub-id pub-id-type="pmcid">PMC8822996</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kanaya</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Araneta</surname><given-names>M.R.G.</given-names></name><name name-style="western"><surname>Saydah</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Gregg</surname><given-names>E.W.</given-names></name><etal/></person-group><article-title>Prevalence of diabetes by race and ethnicity in the United States, 2011&#8211;2016</article-title><source>JAMA</source><volume>322</volume><year>2019</year><fpage>2389</fpage><lpage>2398</lpage><pub-id pub-id-type="pmid">31860047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.19365</pub-id><pub-id pub-id-type="pmcid">PMC6990660</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Lamprea-Montealegre</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zelnick</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>N.</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>I.H.</given-names></name></person-group><article-title>Prevalence of hypertension and cardiovascular risk according to blood pressure thresholds used for diagnosis</article-title><source>Hypertension</source><volume>72</volume><year>2018</year><fpage>602</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">30354757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.118.11609</pub-id><pub-id pub-id-type="pmcid">PMC6205214</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Welborn</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Dhaliwal</surname><given-names>S.S.</given-names></name></person-group><article-title>Preferred clinical measures of central obesity for predicting mortality</article-title><source>Eur J Clin Nutr</source><volume>61</volume><year>2007</year><fpage>1373</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">17299478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ejcn.1602656</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Hirode</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>R.J.</given-names></name></person-group><article-title>Trends in the prevalence of metabolic syndrome in the United States, 2011&#8211;2016</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>2526</fpage><lpage>2528</lpage><pub-id pub-id-type="pmid">32573660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.4501</pub-id><pub-id pub-id-type="pmcid">PMC7312413</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Jaber</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Mirbolouk</surname><given-names>M.</given-names></name><name name-style="western"><surname>DeFilippis</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Maziak</surname><given-names>W.</given-names></name><name name-style="western"><surname>Keith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Electronic cigarette use prevalence, associated factors, and pattern by cigarette smoking status in the United States from NHANES (National Health and Nutrition Examination Survey) 2013&#8211;2014</article-title><source>J Am Heart Assoc</source><volume>7</volume><year>2018</year><object-id pub-id-type="publisher-id">e008178</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.117.008178</pub-id><pub-id pub-id-type="pmcid">PMC6064855</pub-id><pub-id pub-id-type="pmid">30007934</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Denniston</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Klevens</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>McKnight-Eily</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Jiles</surname><given-names>R.B.</given-names></name></person-group><article-title>Association of hepatitis C virus with alcohol use among U.S. adults: NHANES 2003&#8211;2010</article-title><source>Am J Prev Med</source><volume>51</volume><year>2016</year><fpage>206</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">27178884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2016.02.033</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Cave</surname><given-names>M.</given-names></name><name name-style="western"><surname>Appana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Falkner</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>McClain</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Brock</surname><given-names>G.</given-names></name></person-group><article-title>Polychlorinated biphenyls, lead, and mercury are associated with liver disease in American adults: NHANES 2003&#8211;2004</article-title><source>Environ Health Perspect</source><volume>118</volume><year>2010</year><fpage>1735</fpage><lpage>1742</lpage><pub-id pub-id-type="pmid">21126940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.1002720</pub-id><pub-id pub-id-type="pmcid">PMC3002193</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Freedman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Ogden</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Flegal</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Serdula</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>W.H.</given-names></name></person-group><article-title>Childhood overweight and family income</article-title><source>MedGenMed</source><volume>9</volume><year>2007</year><fpage>26</fpage><pub-id pub-id-type="pmcid">PMC1994830</pub-id><pub-id pub-id-type="pmid">17955082</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Ruhl</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Everhart</surname><given-names>J.E.</given-names></name></person-group><article-title>Fatty liver indices in the multiethnic United States national health and nutrition examination survey</article-title><source>Aliment Pharmacol Ther</source><volume>41</volume><year>2015</year><fpage>65</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">25376360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.13012</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Dang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hirode</surname><given-names>G.</given-names></name><name name-style="western"><surname>Singal</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>R.J.</given-names></name></person-group><article-title>Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases</article-title><source>Am J Gastroenterol</source><volume>115</volume><year>2020</year><fpage>96</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">31517639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ajg.0000000000000380</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Hales</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Fryar</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Ogden</surname><given-names>C.L.</given-names></name></person-group><article-title>Prevalence of obesity and severe obesity among adults: United States, 2017&#8211;2018</article-title><source>NCHS Data Brief</source><year>2020</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">32487284</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Hofmeister</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Barranco</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>E.W.</given-names></name><etal/></person-group><article-title>Estimating prevalence of hepatitis C virus infection in the United States, 2013&#8211;2016</article-title><source>Hepatology</source><volume>69</volume><year>2019</year><fpage>1020</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">30398671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.30297</pub-id><pub-id pub-id-type="pmcid">PMC6719781</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Fay</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Feuer</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Midthune</surname><given-names>D.N.</given-names></name></person-group><article-title>Permutation tests for joinpoint regression with applications to cancer rates</article-title><source>Stat Med</source><volume>19</volume><year>2000</year><fpage>335</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">10649300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-0258(20000215)19:3&lt;335::aid-sim336&gt;3.0.co;2-z</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Peduzzi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Concato</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kemper</surname><given-names>E.</given-names></name><name name-style="western"><surname>Holford</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Feinstein</surname><given-names>A.R.</given-names></name></person-group><article-title>A&#160;simulation study of the number of events per variable in logistic regression analysis</article-title><source>J&#160;Clin Epidemiol</source><volume>49</volume><year>1996</year><fpage>1373</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">8970487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0895-4356(96)00236-3</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="book" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y.C.</given-names></name></person-group><series>Multiple imputation for missing data: Concepts and new development (Version 9.0)[J]</series><volume>49</volume><year>2010</year><publisher-name>SAS Institute Inc</publisher-name><publisher-loc>Rockville, MD</publisher-loc><fpage>12</fpage></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Reja</surname><given-names>D.</given-names></name><name name-style="western"><surname>Makar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Visaria</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karanfilian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rustgi</surname><given-names>V.</given-names></name></person-group><article-title>Blood lead level is associated with advanced liver fibrosis in patients with non-alcoholic fatty liver disease: a nationwide survey (NHANES 2011&#8211;2016)</article-title><source>Ann Hepatol</source><volume>19</volume><year>2020</year><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">32376236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.aohep.2020.03.006</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Hyder</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>D.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Firoozmand</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cadmium exposure and liver disease among US adults</article-title><source>J&#160;Gastrointest Surg</source><volume>17</volume><year>2013</year><fpage>1265</fpage><lpage>1273</lpage><pub-id pub-id-type="pmid">23636881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11605-013-2210-9</pub-id><pub-id pub-id-type="pmcid">PMC3974907</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Sterling</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Lissen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clumeck</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sola</surname><given-names>R.</given-names></name><name name-style="western"><surname>Correa</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection</article-title><source>Hepatology</source><volume>43</volume><year>2006</year><fpage>1317</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">16729309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.21178</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Prosper</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schussel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aberle</surname><given-names>D.</given-names></name></person-group><article-title>Lung cancer screening in African Americans: the time to act is now</article-title><source>Radiol Imaging Cancer</source><volume>2</volume><year>2020</year><object-id pub-id-type="publisher-id">e200107</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/rycan.2020200107</pub-id><pub-id pub-id-type="pmcid">PMC7983712</pub-id><pub-id pub-id-type="pmid">33778737</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Montgomery</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Bayliss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Nardo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Keenan</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Miotto</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control</article-title><source>Nat Commun</source><volume>13</volume><year>2022</year><fpage>1259</fpage><pub-id pub-id-type="pmid">35273160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-28889-2</pub-id><pub-id pub-id-type="pmcid">PMC8913628</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Housman</surname><given-names>D.</given-names></name></person-group><article-title>Lead toxicity and genetics in Flint, MI</article-title><source>NPJ Genom Med</source><volume>1</volume><year>2016</year><object-id pub-id-type="publisher-id">16018</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npjgenmed.2016.18</pub-id><pub-id pub-id-type="pmcid">PMC4936820</pub-id><pub-id pub-id-type="pmid">27398227</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="book" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>World Health Organization</surname></name></person-group><part-title>Preventing disease through healthy environments. Exposure to cadmium: a major public health concern</part-title><year>2019</year><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Wijarnpreecha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thongprayoon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scribani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ungprasert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cheungpasitporn</surname><given-names>W.</given-names></name></person-group><article-title>Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA</article-title><source>Eur J Gastroenterol Hepatol</source><volume>30</volume><year>2018</year><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">29215435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MEG.0000000000001045</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sinnott-Armstrong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wagschal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wark</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Camporez</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>A&#160;microRNA linking human positive selection and metabolic disorders</article-title><source>Cell</source><volume>183</volume><year>2020</year><fpage>684</fpage><lpage>701.e614</lpage><pub-id pub-id-type="pmid">33058756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.09.017</pub-id><pub-id pub-id-type="pmcid">PMC8092355</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Winters</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Shaltiel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sarpel</surname><given-names>U.</given-names></name><name name-style="western"><surname>Branch</surname><given-names>A.D.</given-names></name></person-group><article-title>Liver cancer has a distinctive profile in Black patients: current screening guidelines may be inadequate</article-title><source>Hepatol Commun</source><volume>6</volume><year>2022</year><fpage>8</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">34558225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep4.1771</pub-id><pub-id pub-id-type="pmcid">PMC8710783</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Shaltiel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siderides</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gleeson</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pletcher</surname><given-names>E.R.</given-names></name><etal/></person-group><article-title>Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype</article-title><source>Cancer</source><volume>127</volume><year>2021</year><fpage>1395</fpage><lpage>1406</lpage><pub-id pub-id-type="pmid">33629759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.33377</pub-id><pub-id pub-id-type="pmcid">PMC8084866</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Scaglione</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kliethermes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shoham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Durazo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luke</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The epidemiology of cirrhosis in the United States: a population-based study</article-title><source>J&#160;Clin Gastroenterol</source><volume>49</volume><year>2015</year><fpage>690</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">25291348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCG.0000000000000208</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Satapathy</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Marella</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Heda</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Ganguli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kirthi Reddy</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Podila</surname><given-names>P.S.B.</given-names></name><etal/></person-group><article-title>African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians</article-title><source>Eur J Gastroenterol Hepatol</source><volume>33</volume><year>2021</year><fpage>388</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">32317586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MEG.0000000000001735</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Smoyer</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Askerova</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials</article-title><source>Future Oncol</source><volume>17</volume><year>2021</year><fpage>3271</fpage><lpage>3280</lpage><pub-id pub-id-type="pmid">34047192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fon-2020-1262</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Cuevas</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>S.</given-names></name></person-group><article-title>African American experiences in healthcare: &#8220;I always feel like I'm getting skipped over&#8221;</article-title><source>Health Psychol</source><volume>35</volume><year>2016</year><fpage>987</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">27175576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/hea0000368</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Browning</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Khoraki</surname><given-names>J.</given-names></name><name name-style="western"><surname>DeAntonio</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Mazzini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mangino</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes</article-title><source>Int J Obes (Lond)</source><volume>42</volume><year>2018</year><fpage>926</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">29437160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ijo.2017.309</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Watt</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahbar</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Vatcheva</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Cirrhosis and advanced fibrosis in Hispanics in Texas: the dominant contribution of central obesity</article-title><source>PLoS One</source><volume>11</volume><year>2016</year><object-id pub-id-type="publisher-id">e0150978</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0150978</pub-id><pub-id pub-id-type="pmcid">PMC4780836</pub-id><pub-id pub-id-type="pmid">26950933</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Rauh</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Landrigan</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Claudio</surname><given-names>L.</given-names></name></person-group><article-title>Housing and health: intersection of poverty and environmental exposures</article-title><source>Ann N Y Acad Sci</source><volume>1136</volume><year>2008</year><fpage>276</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">18579887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1425.032</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Andrasfay</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>N.</given-names></name></person-group><article-title>Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations</article-title><source>Proc Natl Acad Sci U S A</source><volume>118</volume><year>2021</year><object-id pub-id-type="publisher-id">e2014746118</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2014746118</pub-id><pub-id pub-id-type="pmcid">PMC7865122</pub-id><pub-id pub-id-type="pmid">33446511</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Paik</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Golabi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Younossi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Younossi</surname><given-names>Z.M.</given-names></name></person-group><article-title>Changes in the global burden of chronic liver diseases drom 2012 to 2017: the growing impact of NAFLD</article-title><source>Hepatology</source><volume>72</volume><year>2020</year><fpage>1605</fpage><lpage>1616</lpage><pub-id pub-id-type="pmid">32043613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.31173</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Perumpail</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Gadiparthi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cholankeril</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States</article-title><source>Hepatology</source><volume>69</volume><year>2019</year><fpage>1064</fpage><lpage>1074</lpage><pub-id pub-id-type="pmid">30014489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.30161</pub-id><pub-id pub-id-type="pmcid">PMC6709988</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary data</title><p id="p0190">The following are the supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Multimedia component 2</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material content-type="local-data" id="mmc3" position="float" orientation="portrait"><caption><title>Multimedia component 3</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc3.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material content-type="local-data" id="mmc4" position="float" orientation="portrait"><caption><title>Multimedia component 4</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc4.pdf" position="float" orientation="portrait"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0185">The authors thank Dr Kerry Willis (<funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/100001259</institution-id><institution>National Kidney Foundation</institution></institution-wrap></funding-source>) for highlighting the likely importance of kidney insufficiency.</p></ack><fn-group><fn id="d35e1508"><p id="ntpara0010">Author names in bold designate shared co-first authorship.</p></fn><fn id="appsec2" fn-type="supplementary-material"><p id="p0195">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhepr.2023.100696" id="intref0020">https://doi.org/10.1016/j.jhepr.2023.100696</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>